Executive SummaryPresident James Block becomes chairman. He fills a post vacated by his uncle Leonard Block, who assumes the newly created position of senior chairman of the family-controlled business. Exec VP Thomas Block, son of Leonard Block, is promoted to president. His former responsibilities are taken over by Donald LeSieur, who continues to head the company's U.S. marketing activities. Senior VP Michael Alfano and VP John Peters elected to board, expanding the number of directors to 12.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.